Literature DB >> 34514532

A rebuttal letter to the letter ID number CLRH-D-21-00,836 entitled "On the efficacy and safety of rituximab therapy in patients with systemic sclerosis disease: missing points, bottlenecks, over-exaggeration and discrepancies".

Maliheh Moradzadeh1, Mehrdad Aghaei1, Zahra Mehrbakhsh2,3, Zahra Arab-Bafrani4,5, Nafiseh Abdollahi6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34514532     DOI： 10.1007/s10067-021-05832-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  2 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Effects of rituximab in connective tissue disorders related interstitial lung disease.

Authors:  Gemma Lepri; Jerome Avouac; Paolo Airò; Francisco Anguita Santos; Silvia Bellando-Randone; Jelena Blagojevic; Francisco Garcia Hernàndez; Jose Antonio Gonzalez Nieto; Serena Guiducci; Suzana Jordan; Vidya Limaye; Britta Maurer; Albert Selva-O'Callaghan; Valeria Riccieri; Oliver Distler; Marco Matucci-Cerinic; Yannick Allanore
Journal:  Clin Exp Rheumatol       Date:  2016-10-14       Impact factor: 4.473
  2 in total
  1 in total

Review 1.  [Biologics for connective tissue diseases and vasculitides].

Authors:  Bernhard Hellmich; Joerg C Henes
Journal:  Internist (Berl)       Date:  2022-01-14       Impact factor: 0.743
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.